KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its underwritten public offering of 11,250,000 shares of common stock at a price to the public of $4.00 per share. The gross proceeds to Trevena from this offering are expected to be approximately $45,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Trevena. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,687,500 additional shares of common stock from Trevena at the public offering price. The offering is expected to close on December 10, 2014, subject to customary closing conditions.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
